DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

332 Gupta S, Wright HM. Nebivolol: A highly selective β 1
-adrenergic
receptor blocker that causes vasodilation by increasing nitric
oxide. Cardiovasc Ther, 2008, 26:189–202.
Hayashi Y, Maze M. α 2
Adrenoceptor agonists and anaesthesia.
Br J Anaesth, 1993, 71:108–118.
Henness S, Harrison TS, Keating GM. Ocular carteolol. A review
of its use in the management of glaucoma and ocular hypertension.
Drugs Aging, 2007, 24:509–525.
Hollenberg SM, Kavinsky CJ, Parrillo JE. Cardiogenic shock.
Ann Intern Med, 1999, 131:47–59.
Hu ZW, Shi XY, Hoffman BB. Doxuzosin inhibits proliferation
and migration of human vascular smooth-muscle cells independent
of α 1
-adrenergic receptor antagonism. J Cardiovasc
Pharmacol, 1998, 31:833–839.
Ignarro LJ. Different pharmacological properties of two enantiomers
in a unique β-blocker, nebivolol. Cardiovasc Ther,
2008, 26:115–134.
Ignarro LJ, Byrns RE, Trinh K, et al. Nebivolol: A selective β 1
adrenergic receptor antagonist that relaxes vascular smooth
muscle by nitric-oxide and cyclic GMP-dependent mechanisms.
Nitric Oxide, 2002, 7:75–82.
Ishii Y, Nakamura K, Tsutsumi K, et al. Drug interaction between
cimetidine and timolol ophthalmic solution: effect on heart
rate and intraocular pressure in healthy Japanese volunteers.
J Clin Pharmacol, 2000, 40:193–199.
Keating GM, Jarvis B. Carvedilol: A review of its use in chronic
heart failure. Drugs, 2003, 63:1697–1741.
Kenny B, Miller A, Williamson I, et al. Evaluation of the pharmacological
selectivity profile of α 1
adrenoceptor antagonists
at prostatic α 1
adrenoceptors: Binding, functional and in vivo
studies. Br J Pharmacol, 1996, 118:871–878.
Khouri A, Realini T, Fechtner RD. Use of fixed dose combination
drugs for the treatment of glaucoma. Drugs Aging, 2007,
24:1007–1016.
Kühlkamp V, Bosch R, Mewis C, Seipel L. Use of β-blockers in
atrial fibrillation. Am J Cardiovasc Drugs, 2002, 2:37–42.
Kyprianou N. Doxazosin and terazosin suppress prostate growth
by inducing apoptosis. Clinical significance. J Urol, 2003,
169:1520–1525.
Lefebvre J, Poirier L, Poirier P, et al. The influence of CYP2D6
phenotype on the clinical response of nebivolol in patients with
essential hypertension. Br J Clin Pharmacol, 2007, 63: 575–582.
Liggett SB, Tepe NM, Lorenz JN, et al. Early and delayed consequences
of β 2
-adrenergic receptor overexpression in mouse
hearts: Critical role for expression level. Circulation, 2000,
101:1707–1714.
Lipworth BJ. Long acting β 2
adrenoceptor agonists: a smart
choice for asthma? Trends Pharmacol Sci, 2007, 28:257–262.
Lefkowitz RJ, Rockman HA, Koch WJ. Catecholamines, cardiac
β-adrenergic receptors, and heart failure. Circulation, 2000,
101:1634–1637.
LePor H, Williford W, Barry M, et al. The efficacy of terazosin,
finasteride, or both in begign prostatic hyperplasia. N Eng J
Med, 1996, 335:533–539.
Ma XL, Yue TL, Lopez BL, et al. Carvedilol, a new β adrenoreceptor
blocker and free radical scavenger, attenuates myocardial
ischemia–reperfusion injury in hypercholesterolemic
rabbits. J Pharmacol Exp Ther, 1996, 277:128–136.
Maack C, Cremers B, Flesch M, et al. Different intrinsic activities
of bucindolol, carvedilol and metoprolol in human failing
myocardium. Br J Pharmacol, 2000, 130:1131–1139.
SECTION II
NEUROPHARMACOLOGY
Maggioni AP, Sinagra G, Opasich C, et al. β Blockers in patients
with congestive heart failure: Guided use in clinical practice
investigators. Treatment of chronic heart failure with β adrenergic
blockade beyond controlled clinical trials: The BRING-UP
experience. Heart, 2003, 89:299–305.
Man in’t Veld AJ, Van den Meiracker AH, Schalekamp MA. Do
β blockers really increase peripheral vascular resistance?
Review of the literature and new observations under basal conditions.
Am J Hypertens, 1988, 1:91–96.
Marik PE, Iglesias J. Low-dose dopamine does not prevent
acute renal failure in patients with septic shock and oliguria.
NORASEPT II Study Investigators. Am J Med, 1999,
107:387–390.
Matera MG, Cazzola M. Ultra-long acting β 2
-adrenoceptor agonist.
An emerging therapeutic option for asthma and COPD.
Drugs, 2007, 67:503–515.
McClellan KJ, Wiseman LR, Wilde MI. Midodrine. A review of
its therapeutic use in the management of orthostatic hypotension.
Drugs Aging, 1998, 12:76–86.
McConnell JD, Roehrborn CG, Bautista OM, et al. The longterm
effect of doxazosin, finasteride, and combination therapy
on the clinical progression of benign prostatic hyperplasia.
N Engl J Med, 2003, 349:2387–2398.
McGavin JK, Keating GM. Bisoprolol. A review of its use in
chronic heart failure. Drugs, 2002, 62:2677–2696.
McPherson GA. Current trends in the study of potassium channel
openers. Gen Pharmacol, 1993, 24:275–281.
MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic
heart failure: Metoprolol CR/XL Randomised Intervention
Trial in Congestive Heart Failure (MERIT-HF). Lancet, 1999,
353:2001–2007.
Michel MD, Vrydag W. α 1
-, α 2
- and β-adrenoceptors in the urinary
bladder urethra and prostate. Br J Pharmacolol, 2006,
147:S88–S119.
Mignot E. Sleep, sleep disorders, and hypocretin (orexin). Sleep
Med, 2004, 5:S2–S8.
Mimran A, Ducailar G. Systemic and regional haemodynamic
profile of diuretics and α- and β-blockers. A review comparing
acute and chronic effects. Drugs, 1988, 35(Suppl 6):60–69.
Moen MD, Wagstaff AJ. Nebivolol: A review of its use in the
management of hypertension and chronic heart failure. Drugs,
2006, 66:1389–1409.
Moniotte S, Kobzik L, Feron O, et al. Upregulation of β 3
-
adrenoceptors and altered contractile response to inotropic
amines in human failing myocardium. Circulation, 2001,
103:1649–1655.
Morimoto A, Hasegawa H, Cheng HJ, et al. Endogenous β 3
-
adrenoceptor activation contributes to left ventricular and cardiomyocyte
dysfunction in heart failure. Am J Physiol Heart
Circ Physiol, 2004, 286:H2425–H2433.
Murphy MB, Murray C, Shorten GD. Fenoldopam: A selective
peripheral dopamine receptor agonist for the treatment of
severe hypertension. N Engl J Med, 2001, 345:1548–1557.
Nodari S, Metra M, Dei Cas L. β-Blocker treatment of patients
with diastolic heart failure and atrial hypertension. A prospective,
randomized comparison of the long-term effects of
atenolol vs. nebivolol. Eur J Heart Failure, 2003, 5:621–627.
Osborne NN, Wood JP, Chidlow G, et al. Effectiveness of levobetaxolol
and timolol at blunting retinal ischaemia is related to
their calcium and sodium blocking activities: Relevance to
glaucoma. Brain Res Bull, 2004, 62:525–528.